Fig. 1: EBV 3D chromatin conformation is altered by latency type and PARP inhibition.

A CTCF ChIP-seq profiles in human EBV+ B-cells with type I latency (Mutu, green) or type III latency (LCL, blue), normalized to input chromatin. B Schematic of HiC workflow followed by EBV enrichment and sequencing. The figure was created with BioRender. C Circos graphs of all DNA-DNA contacts with the significance of <0.05 within the type I latency EBV genome (Mutu) derived from HiC matrices. The left circos graph represents the control (untreated genome, blue) and the right represents the type I genome with 2.5 µM olaparib treatment (red). D Linearized type I EBV genome (Mutu) with arcs connecting DNA-DNA contacts derived from HiC matrices. Blue arcs represent chromatin loops that are more frequent in the control genome, red arcs represent chromatin loops that are more frequently observed in the olaparib treated genome, and black arcs are loops that are unchanged between control and treatment. E Circos graph (as described in (C)) for untreated (left, blue) and olaparib treated (right, red) type III EBV genome (LCL). F Linearized type III EBV genome (LCL) as described in (D).